UCSF home page About UCSF UCSF Medical Center
UCSF home page | About UCSF | UCSF Medical Center

Skip to TransPortal content

Decrease the text sizeRestore original text sizeIncrease the text size Enlarge Text
Click to increase the text size. Restore Text
Click to restore original text size. Reduce Text
Click to decrease the text size.
Transporter Database banner  
Decrease the text size | Restore text size | Increase the text size
 Text Sizer image
Home About and More Information Transporter Data Index
Search:  
 

ABCC5

Synonyms: ABC33, DKFZp686C1782, EST277145, MOAT-C, MOATC, MRP5, SMRP, pABC11

Entrez Gene Link

Expression Data
Substrate Information
Inhibitor Information
Clinical Drug-drug Interactions

Expression Data

Expression data for other tissues could be found in http://pharmacogenetics.ucsf.edu/gtex/index.html

Asterisk indicates important transporters in the organ as identified in the organ diagram.

Organ Source Relative Expression
Brain Nishimura    0.0484
Kidney* Nishimura    0.0193
Liver Nishimura    0.00500
Placenta* Nishimura    0.00803
Small Intestine Nishimura    0.00820
Kidney* Mean across all PMT Samples 10.428
Liver Mean across all PMT Samples BLQ
Note that relative expression values should only be compared between entries of the same source.

Back to top

In Vitro Substrates

Substrate Km (μM) Cell System Reference
5-fluorodeoxyuridine monophosphate 1100 MRP5-expressing HEK293 vesicles Pratt, 2005
5-fluorodeoxyuridine monophosphate 1100 MRP5-expressing HEK293 vesicles Pratt, 2006
Carboxydichlorofluorescein 11.6 MRP5-expressing HEK293 vesicles Pratt, 2006
Cyclic AMP 379 MRP5-expressing V79 vesicles Jedlitschky, 2000
Cyclic GMP 2.1 MRP5-expressing V79 vesicles Jedlitschky, 2000
Folic acid 1000 MRP5-expressing HEK293 vesicles Wielinga, 2005
Methotrexate 1200 MRP5-expressing HEK293 vesicles Wielinga, 2005
Methotrexate 1174 MRP5-expressing HEK293 vesicles Pratt, 2006
Methotrexate-glucuronide 700 MRP5-expressing HEK293 vesicles Wielinga, 2005
Pemetrexed 281 MRP5-expressing HEK293 vesicles Pratt, 2006

ND = not determined
1 denotes drugs that can potentially be used as in vitro substrates for studies of the transporter as defined by the FDA as of March 2022
2 denotes drugs that can potentially be used as in vitro inhibitors for studies of the transporter as defined by the FDA as of March 2022
3 denotes drugs that can potentially be used as clinical substrates for studies of the transporter as defined by the FDA as of March 2022
4 denotes drugs that can potentially be used as clinical inhibitors for studies of the transporter as defined by the FDA as of March 2022


Back to top

In Vitro Inhibitors

Inhibitor IC50 (μM) Ki (μM) Substrate used Cell System Reference
5-fluorodeoxyuridine monophosphate 1163 Carboxydichlorofluorescein MRP5-expressing HEK293 vesicles Pratt, 2006
5-nitro-2-(3-phenylpropylamino)-benzoic acid (NPPB) 2 5-fluorodeoxyuridine monophosphate MRP5-expressing HEK293 vesicles Pratt, 2005
5-nitro-2-(3-phenylpropylamino)-benzoic acid (NPPB) 0.102 Carboxydichlorofluorescein MRP5-expressing HEK293 vesicles Pratt, 2006
Benzbromarone 150 9-(2-phosphonomethoxyethyl)adenine (PMEA) MRP4-expressing HEK293 vesicles Reid, 2003
Cyclic GMP 960 5-fluorodeoxyuridine monophosphate MRP5-expressing HEK293 vesicles Pratt, 2005
Cyclic GMP 4855.5 Carboxydichlorofluorescein MRP5-expressing HEK293 vesicles Pratt, 2006
Dipyridamole 30 9-(2-phosphonomethoxyethyl)adenine (PMEA) MRP4-expressing HEK293 vesicles Reid, 2003
Glyburide 15 5-fluorodeoxyuridine monophosphate MRP5-expressing HEK293 vesicles Pratt, 2005
Methotrexate 780 5-fluorodeoxyuridine monophosphate MRP5-expressing HEK293 vesicles Pratt, 2005
Methotrexate 1059 Carboxydichlorofluorescein MRP5-expressing HEK293 vesicles Pratt, 2006
MK-571 17 5-fluorodeoxyuridine monophosphate MRP5-expressing HEK293 vesicles Pratt, 2005
MK-571 200 9-(2-phosphonomethoxyethyl)adenine (PMEA) MRP4-expressing HEK293 vesicles Reid, 2003
MK-571 15.9 Carboxydichlorofluorescein MRP5-expressing HEK293 vesicles Pratt, 2006
Pemetrexed 2110 5-fluorodeoxyuridine monophosphate MRP5-expressing HEK293 vesicles Pratt, 2005
Pemetrexed 442 Carboxydichlorofluorescein MRP5-expressing HEK293 vesicles Pratt, 2006
Pemetrexed 300 Carboxydichlorofluorescein MRP5-expressing HEK293 vesicles Pratt, 2006
Probenecid 70 5-fluorodeoxyuridine monophosphate MRP5-expressing HEK293 vesicles Pratt, 2005
Probenecid 200 9-(2-phosphonomethoxyethyl)adenine (PMEA) MRP4-expressing HEK293 vesicles Reid, 2003
Probenecid 34 Carboxydichlorofluorescein MRP5-expressing HEK293 vesicles Pratt, 2006
Sildenafil 580 5-fluorodeoxyuridine monophosphate MRP5-expressing HEK293 vesicles Pratt, 2005
Sildenafil 80 9-(2-phosphonomethoxyethyl)adenine (PMEA) MRP4-expressing HEK293 vesicles Reid, 2003
Sildenafil 0.267 Cyclic GMP MRP5-expressing V79 vesicles Jedlitschky, 2000
Sulfinpyrazone 300 9-(2-phosphonomethoxyethyl)adenine (PMEA) MRP4-expressing HEK293 vesicles Reid, 2003
Sulfinpyrazone 103.2 Carboxydichlorofluorescein MRP5-expressing HEK293 vesicles Pratt, 2006
Trequinsin 580 5-fluorodeoxyuridine monophosphate MRP5-expressing HEK293 vesicles Pratt, 2005
Trequinsin 30 9-(2-phosphonomethoxyethyl)adenine (PMEA) MRP4-expressing HEK293 vesicles Reid, 2003
Trequinsin 218 Carboxydichlorofluorescein MRP5-expressing HEK293 vesicles Pratt, 2006
Trequinsin 0.24 Cyclic GMP MRP5-expressing V79 vesicles Jedlitschky, 2000
Zaprinast 20 5-fluorodeoxyuridine monophosphate MRP5-expressing HEK293 vesicles Pratt, 2005
Zaprinast 250 9-(2-phosphonomethoxyethyl)adenine (PMEA) MRP4-expressing HEK293 vesicles Reid, 2003
Zaprinast 32.3 Carboxydichlorofluorescein MRP5-expressing HEK293 vesicles Pratt, 2006

ND = not determined
1 denotes drugs that can potentially be used as in vitro substrates for studies of the transporter as defined by the FDA as of March 2022
2 denotes drugs that can potentially be used as in vitro inhibitors for studies of the transporter as defined by the FDA as of March 2022
3 denotes drugs that can potentially be used as clinical substrates for studies of the transporter as defined by the FDA as of March 2022
4 denotes drugs that can potentially be used as clinical inhibitors for studies of the transporter as defined by the FDA as of March 2022


Back to top

Clinical Drug-Drug Interactions

DDI Implicated Transporter Interacting Drug Affected Drug AUC Cmax CLR CL/F t1/2 Effect on PD Reference More Details
Clinical PK Impact(fold change)
1 MRPs Probenecid Cefmetazole 1.6 NS 0.6 0.6 1.5 ND Ko, 1989 DDI 1
2 OATs/MRPs Probenecid Ciprofloxacin 1.7 NS 0.4 0.6 1.5 ND Jaehde, 1995 DDI 2
3 OATs/MRPs Probenecid Furosemide 2.7 1.5 0.3 0.4 1.7 ND Vree, 1995 DDI 3

The transporters are implicated by in vitro data and/or studies in humans with genetic polymorphisms of the transporter
DDI = Drug Drug Interaction
PK = pharmacokinetic
PD = pharmacodynamic
ND = not determined
NS = not significant
N/A = information not available
Calculation of Fold Change: fold change in the presence of the interacting drug = (value with interacting drug)/(value without interacting drug)
fold change > 1: increase in pharmacokinetic value
fold change < 1: decrease in pharmacokinetic value
1 denotes drugs that can potentially be used as in vitro substrates for studies of the transporter as defined by the FDA as of March 2022
2 denotes drugs that can potentially be used as in vitro inhibitors for studies of the transporter as defined by the FDA as of March 2022
3 denotes drugs that can potentially be used as clinical substrates for studies of the transporter as defined by the FDA as of March 2022
4 denotes drugs that can potentially be used as clinical inhibitors for studies of the transporter as defined by the FDA as of March 2022


Back to top

Contact us | Glossary

Blue banner